loading...| Preferred Name | Valsartan | |
| Synonyms |
|
|
| Definitions |
An orally active nonpeptide triazole-derived antagonist of angiotensin (AT) II with antihypertensive properties. Valsartan selectively and competitively blocks the binding of angiotensin II to the AT1 subtype receptor in vascular smooth muscle and the adrenal gland, preventing AT II-mediated vasoconstriction, aldosterone synthesis and secretion, and renal reabsorption of sodium, and resulting in vasodilation, increased excretion of sodium and water, a reduction in plasma volume, and a reduction in blood pressure. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C47781 |
|
| CAS_Registry |
137862-53-4 |
|
| CHEBI_ID |
CHEBI:9927 |
|
| Chemical_Formula |
C24H29N5O3 |
|
| code |
C47781 |
|
| Contributing_Source |
FDA |
|
| definition |
An orally active nonpeptide triazole-derived antagonist of angiotensin (AT) II with antihypertensive properties. Valsartan selectively and competitively blocks the binding of angiotensin II to the AT1 subtype receptor in vascular smooth muscle and the adrenal gland, preventing AT II-mediated vasoconstriction, aldosterone synthesis and secretion, and renal reabsorption of sodium, and resulting in vasodilation, increased excretion of sodium and water, a reduction in plasma volume, and a reduction in blood pressure. |
|
| FDA_UNII_Code |
80M03YXJ7I |
|
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C173383 |
|
| label |
Valsartan |
|
| Legacy Concept Name |
Valsartan |
|
| NCI_Drug_Dictionary_ID |
464172 |
|
| PDQ_Closed_Trial_Search_ID |
464172 |
|
| PDQ_Open_Trial_Search_ID |
464172 |
|
| Preferred_Name |
Valsartan |
|
| prefixIRI |
NCIT:C47781 |
|
| prefLabel |
Valsartan |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0216784 |
|
| subClassOf |